ABOUT US

Healthcare Royalty (“HCRx”) is a leading royalty acquisition company founded in 2006 that is majority owned by KKR. Over two decades, the HCRx team has developed a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets, committing over $7 billion in capital on behalf of its investors. Today, HCRx manages approximately $3 billion in assets with a portfolio that spans over 30 therapeutic areas and over 55 products. With offices in New York, Stamford, San Francisco, Boston, London and Miami, HCRx continues to advance biopharmaceutical innovation by providing innovative capital solutions to counterparties.

In July 2025, KKR acquired majority ownership in HCRx to enhance its capabilities in biopharma royalty and credit investing, while expanding the firm’s existing footprint in the life sciences ecosystem. The transaction reflects a long-standing relationship between the two firms and validates HCRx’s leadership in the biopharma royalty industry, an asset class with growing demand. As part of the transaction, HCRx Chairman and CEO Clarke Futch continues to lead the HCRx team and maintains an ongoing substantial minority interest in HCRx. Together, KKR and HCRx are able to more comprehensively serve the landscape of biopharma companies and continue delivering value to stakeholders.

Please scroll through our timeline to see how we got here.

HealthCare Royalty Timeline